Get the Stockscreener App
1.29
2.27%
-0.03
After Hours:
1.26
-0.03
-2.33%
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Repare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market Challenges - MSN
Repare Therapeutics (RPTX) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Layoff Tracker: Kojin Will Soon Close Its Doors, Affecting 25 Employees - BioSpace
What Are You Thinking About Investing In Repare Therapeutics Inc (NASDAQ: RPTX) Stock? - Stocks Register
Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.6363: Will the Stock Break Through? - The InvestChronicle
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Repare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market Challenges By Investing.com - Investing.com South Africa
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
CNL Partners With Repare And Defence Therapeutics For Cancer Research - Canadian Manufacturing
CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Financial Post
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Yahoo Finance
Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3% - MarketBeat
The Market Doesn't Like What It Sees From Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Repare Therapeutics Announces Strategic Changes and Financial Update - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Acquired by Barclays PLC - Defense World
Stifel cuts Repare Therapeutics target to $3, maintains Buy By Investing.com - Investing.com Canada
Repare Therapeutics stock rating cut to Hold at Bloom Burton By Investing.com - Investing.com Canada
Repare Therapeutics Shifts Focus to Phase 1 Programs - TipRanks
Repare cans plans for phase 3 cancer combo trial in latest money-saving move - Fierce Biotech
Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment - MarketWatch
Repare Therapeutics Streamlines Pipeline, Extends Cash Runway to 2027 with Strategic Restructuring - StockTitan
Eton Pharmaceuticals (NASDAQ:ETON) versus Repare Therapeutics (NASDAQ:RPTX) Financial Survey - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World
Repare Therapeutics stock hits 52-week low at $1.22 - Investing.com
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):